.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Covington
Cantor Fitzgerald
Boehringer Ingelheim
US Department of Justice
Queensland Health
Fuji
Express Scripts
McKinsey
Mallinckrodt

Generated: June 25, 2017

DrugPatentWatch Database Preview

RETIN-A Drug Profile

« Back to Dashboard

Which patents cover Retin-a, and when can generic versions of Retin-a launch?

Retin-a is a drug marketed by Valeant Intl, Valeant Bermuda, and Valeant Pharms North. and is included in seven NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

The generic ingredient in RETIN-A is tretinoin. There are twenty-four drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the tretinoin profile page.

Summary for Tradename: RETIN-A

Patents:0
Applicants:3
NDAs:7
Suppliers / Packagers: see list5
Bulk Api Vendors: see list93
Clinical Trials: see list9
Patent Applications: see list9,769
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:RETIN-A at DailyMed

Pharmacology for Tradename: RETIN-A

Ingredient-typeRetinoids
Drug ClassRetinoid
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Intl
RETIN-A
tretinoin
SOLUTION;TOPICAL016921-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe
Valeant Intl
RETIN-A
tretinoin
GEL;TOPICAL017579-002Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe
Valeant Pharms North
RETIN-A
tretinoin
CREAM;TOPICAL017340-001Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe
Valeant Intl
RETIN-A MICRO
tretinoin
GEL;TOPICAL020475-002May 10, 2002ABRXYesYes5,955,109► Subscribe ► Subscribe
Valeant Intl
RETIN-A
tretinoin
SWAB;TOPICAL016921-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RETIN-A

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms North
RETIN-A
tretinoin
CREAM;TOPICAL017340-001Approved Prior to Jan 1, 19823,729,568► Subscribe
Valeant Bermuda
RETIN-A
tretinoin
CREAM;TOPICAL019049-001Sep 16, 19883,729,568► Subscribe
Valeant Bermuda
RETIN-A
tretinoin
CREAM;TOPICAL019049-001Sep 16, 19883,906,108► Subscribe
Valeant Intl
RETIN-A
tretinoin
SOLUTION;TOPICAL016921-001Approved Prior to Jan 1, 19823,729,568► Subscribe
Valeant Pharms North
RETIN-A
tretinoin
CREAM;TOPICAL017340-001Approved Prior to Jan 1, 19823,906,108► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: RETIN-A

Drugname Dosage Strength RLD Submissiondate
tretinoinGel0.04%Retin-A Micro12/20/2010
tretinoinGel0.1%Retin-A Micro7/8/2010
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Mallinckrodt
Express Scripts
Johnson and Johnson
AstraZeneca
US Army
Federal Trade Commission
Deloitte
Argus Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot